Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success

Journal of Hepatology

Volumn 46, Issue 6, 2007, Pages 988-991

  Samuel, Didier ^a,b,c   Roche, Bruno ^a,b,c  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; OKT 3; PEGINTERFERON; RIBAVIRIN; STEROID; THYMOCYTE ANTIBODY;

ANEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; GRAFT VERSUS HOST REACTION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INCIDENCE; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN;

EID: 34247610929     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.03.004     Document Type: Editorial

References (30)

1. Liver Transplant Registry - ELTR. Registry for the European liver transplant association, data analysis, 05/1968-12/2005, Available from: http://www.eltr.org.
2. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., et al. report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France). J Hepatol 45 (2006) 127-143
3. Féray C., Caccamo L., Alexander G.J.M., Ducot B., Gugenheim J., Casanovas T., et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 117 (1999) 619-625
4. Prieto M., Berenguer M., Rayon J.M., Cordoba J., Arguello L., Carrasco D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29 (1999) 250-256
5. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 32 (2000) 673-684
6. Berenguer M., Prieto M., Rayon J.M., Mora J., Pastor M., Ortiz V., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32 (2000) 852-858
7. McCaughan G.W., and Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 40 (2004) 368-374
8. Doughty A.L., Painter D.M., and McCaughan G.W. Post-transplant quasi-species pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 32 (2000) 126-134
9. Gane E., Naoumov N., Qian K., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 110 (1996) 167-177
10. Di Martino V., Saurini F., Samuel D., Gigou M., Dussaix E., Reynes M., et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 26 (1997) 1343-1350
11. Feray C., Gigou M., Samuel D., Paradis V., Mishiro S., Maertens G., et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 108 (1995) 1088-1096
12. Gigou M., Roque Afonso A.M., Falissard B., Penin F., Dussaix E., and Féray C. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 75 (2001) 11292-11297
13. Rifai K., Sebagh M., Karam V., Saliba F., Azoulay D., Adam R., et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 41 (2004) 446-453
14. Berenguer M., Prieto M., San Juan F., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002) 202-210
15. Wali M., Harrison R.F., Gow P.J., and Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 (2002) 248-252
16. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002) 680-687
17. Shergill A.K., Khalili M., Straley S., Bollinger K., Roberts J.P., Ascher N.A., et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 5 (2005) 118-124
18. Castells L., Vargas V., Allende H., Bilbao I., Luis L.J., Margarit C., et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 43 (2005) 53-59
19. Neumann U.P., Berg T., Bahra M., Seeehofer D., Langrehr J.M., Neuhaus R., et al. Fibrosis progression after liver transplantation In patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
20. Blasco A., Forns X., Carrion J.A., Garcia-Pagan J.C., Gilabert R., Rimola A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis recurrence after liver transplantation. Hepatology 43 (2006) 492-499
21. Samuel D., Bizollon T., Féray C., Roche B., Si Ahmed S.N., Lemonnier C., et al. Interferon alfa 2b plus ribavirin in patients with recurrent HCV infection after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
22. Bizollon T., Ahmed S.N.S., Radenne S., Chevallier M., Parvaz P., Guichard S., et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52 (2003) 283-287
23. Féray C., Samuel D., Gigou M., Paradis V., David M.F., Lemonnier C., et al. An open trial of Interferon alfa recombinant for hepatitis C after liver transplantation : antiviral effects and risk of rejection. Hepatology 22 (1995) 1084-1089
24. Bizollon T., Palazzo U., Ducerf C., Chevallier M., Elliot M., Baulieux J., et al. Pilot study of the combination of Interferon alfa and Ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 26 (1997) 500-504
25. Lavezzo B., Franchello A., Smedile A., David E., Barbui A., Torrani M., et al. Treatment of recurrent hepatitis C in liver transplants : efficacy of a six versus a twelve month course of interferon alpha 2b with ribavirin. J Hepatol 37 (2002) 247-252
26. Chalasani N., Manzarbeitia C., Ferenci P., Vogel W., Fontana R.J., Voigt M., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation : two randomized, controlled trials. Hepatology 41 (2005) 289-298
27. Dumortier J., Scoazec J.Y., Chevallier P., and Boillot O. treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alpha-2b and ribavirin combination. J Hepatol 40 (2004) 669-674
28. Rodriguez-Luna H., Khatib A., Shrama P., De Petris G., Williams J.W., Ortiz J., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 77 (2004) 190-194
29. Angelico M., Petrolati A., Lionetti R., Lenci I., Bura P., Donato M.F., et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 46 (2007) 1009-1017
30. Bizollon T., Pradat P., Mabrut J.Y., Chevallier M., Adham M., Radenne S., et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 5 (2005) 1909-1913